Universität zu Köln

Schneider, Christian A. and Pfister, Roman (2022). Treatment of heart failure with preserved ejection fraction with SGLT2 inhibitors: new therapy standard? Herz, 47 (5). S. 395 - 401. MUNICH: URBAN & VOGEL. ISSN 1615-6692

Full text not available from this repository.

Abstract

Heart failure with preserved ejection fraction (HFpEF) is a common and difficult-to-treat heart disease. Approximately half of patients with heart failure suffer from this form, and mortality is between 5% and 7% per year. Previous therapeutic trials for the treatment of HFpEF have been disappointing. However, recent data on therapy with sodium-glucose cotransporter-2 (SGLT2) inhibitors in HFpEF are encouraging. In addition to numerous experimental studies showing improvement in diastolic dysfunction parameters, the EMPEROR-Preserved study demonstrated for the first time clinically that therapy with the SGLT2 inhibitor empagliflozin significantly reduced hospitalization for heart failure. By contrast, cardiovascular mortality was not affected. Differences for patients with and without type 2 diabetes mellitus were not observed. Thus, for the first time, there is an evidence-based treatment option to reduce hospitalization and improve quality of life in these patients. Further studies will show to what extent these beneficial effects will also lead to an improvement in the prognosis of these patients.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Schneider, Christian A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Pfister, Roman UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-662511
DOI:	10.1007/s00059-022-05134-6
Journal or Publication Title:	Herz
Volume:	47
Number:	5
Page Range:	S. 395 - 401
Date:	2022
Publisher:	URBAN & VOGEL
Place of Publication:	MUNICH
ISSN:	1615-6692
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language TYPE-2 DIABETES-MELLITUS; NA+/H+ EXCHANGER; EMPAGLIFLOZIN; STIFFNESS; DAPAGLIFLOZIN; MORTALITY; EXERCISE; OUTCOMES; DISEASE Multiple languages Cardiac & Cardiovascular Systems Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/66251